Fisher Asset Management LLC Acquires Shares of 12,800 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Fisher Asset Management LLC acquired a new stake in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 12,800 shares of the company’s stock, valued at approximately $51,000. Fisher Asset Management LLC owned 0.15% of Citius Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. IFP Advisors Inc grew its position in shares of Citius Pharmaceuticals by 21.2% in the 4th quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock worth $162,000 after buying an additional 7,083 shares during the period. Geode Capital Management LLC grew its position in shares of Citius Pharmaceuticals by 14.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after buying an additional 232,656 shares during the period. Virtu Financial LLC bought a new position in Citius Pharmaceuticals in the 3rd quarter worth about $50,000. Chelsea Counsel Co. boosted its stake in Citius Pharmaceuticals by 9.8% in the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock worth $141,000 after purchasing an additional 25,000 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Citius Pharmaceuticals in the 3rd quarter worth about $47,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Stock Performance

CTXR opened at $1.79 on Friday. The company’s 50-day simple moving average is $2.82 and its two-hundred day simple moving average is $6.77. Citius Pharmaceuticals, Inc. has a 52-week low of $1.47 and a 52-week high of $26.75.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, February 14th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($1.25) by ($0.05). On average, sell-side analysts predict that Citius Pharmaceuticals, Inc. will post -4.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CTXR has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, February 18th.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.